A practical reference on tuftsin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-27 and is reviewed periodically as new material appears.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analog of the tetrapeptide tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Reported consistently across pharmacopoeial descriptions |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| Solubility | Freely soluble in water | Aqueous buffers; poor in nonpolar solvents |
| Typical storage temperature | -20 degrees Celsius | Lyophilized powder; protect from moisture |
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Limitations While it is an exceptional tool, constraints do arise, particularly in practical applications. In some cases, the need for externally added reagents arises to integrate dienophiles into biomolecules. A compromise in stability can also occur due to the instability of the fastest alkenes because of isomerization of trans-cyclooctenes to cis. Regardless, the reaction continues to be widely used as a result of the critical role it plays in several applications.
=== Extensions === The area under the effect curve (AUEC) is an integral of the effect of a drug over time, estimated as a previously-established function of concentration. It was proposed to be used instead of AUC in animal-to-human dose translation, as computer simulation shows that it could cope better with half-life and dosing schedule variations than AUC. This is an example of a PK/PD model, which combines pharmacokinetics and pharmacodynamics.
Andrew Welsh has served as President of the board since September 2025, with Vice-President Anthony Di Pietro serving since March 2026. Essendon's board members are Andrew Welsh, Tim Roberts, David Wills, Dorothy Hisgrove, Andrew Muir, Kate O'Sullivan, Anthony Howard AM KC, and Catriona Larritt.
Sources: en.wikipedia.org
=== Monitoring === The Epidermolysis Bullosa Disease Activity and Scarring index (EBDASI) is a scoring system that objectively quantifies the severity of EB. The EBDASI is a tool for clinicians and patients to monitor the severity of the disease. It has also been designed to evaluate the response to new therapies for the treatment of EB. The EBDASI was developed and validated by Professor Dedee Murrell and her team of students and fellows at the St George Hospital, University of New South Wales, in Sydney, Australia. It was presented at the International Investigative Dermatology congress in Edinburgh in 2013 and a paper-based version was published in the Journal of the American Academy of Dermatology in 2014.
Mash et al. (2000), using lower oral doses (10–12 mg/kg) in 27 patients, demonstrated significantly lower objective opiate withdrawal scores in heroin addicts 36 hours after treatment, with self-reports of decreased cocaine and opiate craving and alleviated depression symptoms. Many of these effects appeared sustainable over a one-month post-discharge follow-up.
==== Qualified small business stock gain exclusion ==== The Omnibus Budget Reconciliation Act of 1993 allowed noncorporate taxpayers who acquired qualified small business stock and held the stock for more than five years to exclude from capital gain recognition of up to $10 million or 10 times the taxpayer's basis in the stock, which ever was greater. In order for the stock to qualify, the issuing corporation's aggregate gross assets needed to be no more than $50 million immediately before or after the stock issuance. The OBBBA changed the requirement to hold the stock for at least five years. For qualified small business stock acquired after July 4, 2025, a 50% exclusion is available for stock held at least three years, a 75% exclusion is available for stock held for at least four years, and a 100% continues to be available for stock held for at least five years. The OBBBA also increased the exclusion's limit to $15 million or 10 times the taxpayer's basis in the stock, which ever was greater. The $15-million limit will be subject to annual inflation adjustments in 2027 and thereafter. In addition, the OBBBA now allows the issuing corporation to have an aggregate gross asset limitation of up to $75 million for stock issued after July 4, 2025. The $75-million limit will be subject to annual inflation adjustments in 2027 and thereafter.
Sources: en.wikipedia.org
=== Protandim voluntary recall === In December 2012, LifeVantage issued a voluntary recall of select lots (ten lots in total comprising 247,896 bottles) of Protandim due to potential health risks arising from the possible inclusion of small metal fragments in the final product. In February 2013, the company announced that it was extending the recall to include additional lots of the product, estimating the total cost of the recall at $5.9 million.
=== Target animal safety === In swine, ractopamine is correlated with adverse effects, especially hyperactivity, trembling, and broken limbs, leading to censure by animal rights groups. In a conversation with Boulder Weekly newspaper, Colorado State University Professor of Animal Science Temple Grandin, an expert on animal welfare, described harmful effects of ractopamine on feedlot animals, such as cattle with stiff, sore, and lame limbs, and increased heat stress. In the same column, she also opines that meat from ractopamine-treated animals may be tougher. Ractopamine use is a factor in the incidence of downer pigs, animals that are unable to move or stand.
=== British republicanism === Hitchens was a vocal supporter of republicanism in the United Kingdom, advocating the abolition of the monarchy, and in 1990 published the book-long polemic The Monarchy: A Critique of Britain's Favourite Fetish. His 1998 documentary Princess Diana: The Mourning After accused the British media of playing an essential role in creating a national, unchallengeable, and at times hysterical cult of personality surrounding the death of Diana, Princess of Wales, whereas previously they had been extremely critical of her and the monarchy after she had separated and divorced from Charles, Prince of Wales, and was having an affair with Egyptian billionaire Dodi Fayed. Hitchens claimed the public were behaving irrationally, and that many appeared to not even know why they were mourning. He also scrutinised the level of censorship against criticism of Diana and the monarchy but was accused, in a review by The Independent, of exaggerating on this point.
Merit Award from the National Institute of Health American Society for Bone and Mineral Research Fuller Albright Award Mead Johnson Award Osborne and Mendel Award, the McCollum Award Robert H. Herman Award from the American Society for Clinical Nutrition ACN Award from the American College of Nutrition NIH’s General Clinical Research Center's Program Award for Excellence in Clinical Research Psoriasis Research Achievement Award from the American Skin Association DSM Innovation in Nutrition Award Van Slyke Award from American Association for Clinical Chemistry Linus Pauling Prize In Human Nutrition Delbert A Fisher Research Scholar Award from the Endocrine Society American College of Nutrition's Communication Media Award Institute of Functional Medicine’s LPI Award 2007
Sources: en.wikipedia.org
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.
The first four residues of Selank reproduce the tuftsin sequence Thr-Lys-Pro-Arg. A Pro-Gly-Pro extension at the C-terminus was added to slow enzymatic breakdown and extend residence time.
It holds marketing authorization in Russia, where nasal drop formulations are sold. No equivalent approval exists in the European Union, the United States, or most other countries.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.